Patiromer (Veltassa®) is a crosslinked, insoluble co-polymer drug used as a nonabsorbent potassium binder, approved for treatment of hyperkalemia. Quantitative solid-state C nuclear magnetic resonance (NMR) analysis with comprehensive peak assignment, component quantification, and calculation of mole and weight fractions of monomer units was performed on three doses of patiromer. The workflow is documented in detail. Spectrally edited solid-state C NMR spectra of patiromer show =CH peaks of matching intensity at 116 and 141 ppm, characteristic of -CH=CH vinyl groups. Similar spectral features can be observed in earlier studies but were previously ignored. In this study, the vinyl signals are well-resolved in a 2-s direct polarization (DP) spectrum without and with dipolar dephasing, which confirms that these sp-hybridized carbons are bonded to hydrogen and partially mobile, consistent with vinyl side groups from incompletely reacted divinyl crosslinkers. The vinyl groups account for 1.6% of all carbon, 3% of the monomer units, and nearly 1/3 of the crosslinkers. Furthermore, an unexpected OCH moiety accounting for ∼1.2% of all carbons was identified by spectral editing; its chemical shift of 54 ppm is more consistent with a methyl ester than with a methyl ether. It can originate from incomplete hydrolysis of ∼6% of methyl-2-fluoroacrylate, the main monomer of patiromer. Characteristic cross peaks in two-dimensional H-C heteronuclear correlation NMR confirm the presence of the vinyl and OCH groups. Trace amounts of xanthan gum are also detected. The quantitative C NMR spectrum of patiromer has been matched in a simulation using a model with five monomer units.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpba.2024.116228 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!